sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.
|
phenytoin
|
theophylline
|
EFFECT
|
3967572.xml
|
DDI-MedLine.d7.s4
|
DDI-MedLine.d7.s4.p0
|
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
|
Barbiturates
|
antibiotics
|
EFFECT
|
Hexobarbital_ddi.xml
|
DDI-DrugBank.d457.s0
|
DDI-DrugBank.d457.s0.p1
|
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
|
disulfiram
|
iodoquinol
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s13
|
DDI-DrugBank.d263.s13.p58
|
Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
|
levothyroxine sodium
|
sodium polystyrene sulfonate
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s2
|
DDI-DrugBank.d411.s2.p11
|
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
|
digoxin
|
FLOLAN
|
MECHANISM
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s3
|
DDI-DrugBank.d241.s3.p49
|
Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
|
clorazepate dipotassium
|
chlorpromazine
|
EFFECT
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s1
|
DDI-DrugBank.d335.s1.p2
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
coumarin
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p2
|
ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.
|
combination hormonal contraceptives
|
caffeine
|
EFFECT
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s43
|
DDI-DrugBank.d485.s43.p5
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
Ethanol
|
Flupenthixol
|
NONE
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p51
|
If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.
|
diuretic
|
PRINIVIL
|
ADVISE
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s2
|
DDI-DrugBank.d334.s2.p0
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
furosemide
|
valsartan
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p34
|
Ranitidine also has no effect on eprosartan pharmacokinetics.
|
Ranitidine
|
eprosartan
|
NONE
|
Eprosartan_ddi.xml
|
DDI-DrugBank.d525.s3
|
DDI-DrugBank.d525.s3.p0
|
(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)
|
thiazide diuretics
|
digitalis
|
EFFECT
|
Hydroflumethiazide_ddi.xml
|
DDI-DrugBank.d17.s12
|
DDI-DrugBank.d17.s12.p0
|
Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.
|
Ketoconazole
|
alosetron
|
MECHANISM
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s8
|
DDI-DrugBank.d364.s8.p0
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
efavirenz
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p4
|
In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.
|
HCTZ
|
dofetilide
|
MECHANISM
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s14
|
DDI-DrugBank.d558.s14.p0
|
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
|
propafenone
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s2
|
DDI-DrugBank.d450.s2.p28
|
Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.
|
central nervous system depressants
|
hydroxyzine
|
ADVISE
|
Hydroxyzine_ddi.xml
|
DDI-DrugBank.d308.s1
|
DDI-DrugBank.d308.s1.p0
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
Tagamet
|
theophylline
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p8
|
Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.
|
MAO inhibitors
|
dopamine HCl
|
ADVISE
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s1
|
DDI-DrugBank.d325.s1.p0
|
The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide
|
irbesartan
|
hydrochlorothiazide
|
NONE
|
Irbesartan_ddi.xml
|
DDI-DrugBank.d27.s5
|
DDI-DrugBank.d27.s5.p1
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
VISTIDE
|
aminoglycosides
|
ADVISE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p0
|
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
|
paclitaxel
|
doxorubicin
|
MECHANISM
|
Paclitaxel_ddi.xml
|
DDI-DrugBank.d288.s5
|
DDI-DrugBank.d288.s5.p5
|
Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.
|
Furosemide
|
furosemide
|
NONE
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s7
|
DDI-DrugBank.d132.s7.p2
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
estrogens
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p4
|
Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
|
Amphetamines
|
antihistamines
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s14
|
DDI-DrugBank.d236.s14.p2
|
Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.
|
cimetidine
|
gabapentin
|
MECHANISM
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s30
|
DDI-DrugBank.d438.s30.p0
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
terfenadine
|
ergot derivatives
|
NONE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p63
|
More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor.
|
selegiline
|
entacapone
|
NONE
|
Entacapone_ddi.xml
|
DDI-DrugBank.d455.s8
|
DDI-DrugBank.d455.s8.p0
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
monoamine oxidase inhibitors
|
venlafaxine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p7
|
Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.
|
Vardenafil
|
ketoconazole
|
ADVISE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s9
|
DDI-DrugBank.d198.s9.p2
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
isoniazid
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p12
|
Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.
|
digoxin
|
VAPRISOL
|
MECHANISM
|
Conivaptan_ddi.xml
|
DDI-DrugBank.d315.s1
|
DDI-DrugBank.d315.s1.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Astramorph
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p32
|
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
|
Tagamet
|
Theo-Dur
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s4
|
DDI-DrugBank.d171.s4.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
midazolam
|
triazolam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p859
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
EQUETROTM
|
Cisplatin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p0
|
Cocaine sometimes proves to be fatal when used in combination with heroin.
|
Cocaine
|
heroin
|
EFFECT
|
Heroin_ddi.xml
|
DDI-DrugBank.d514.s4
|
DDI-DrugBank.d514.s4.p0
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
ondansetron
|
NONE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p12
|
Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
|
Anticholinergic agents
|
ipratropium bromide
|
NONE
|
Ipratropium_ddi.xml
|
DDI-DrugBank.d51.s2
|
DDI-DrugBank.d51.s2.p0
|
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
|
methotrexate
|
ciprofloxacin
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s5
|
DDI-DrugBank.d123.s5.p3
|
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
|
Anabolic steroids
|
oxymetholone
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s3
|
DDI-DrugBank.d179.s3.p4
|
When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.
|
INDOCIN
|
probenecid
|
MECHANISM
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s9
|
DDI-DrugBank.d82.s9.p0
|
Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
|
dolasetron
|
rifampin
|
MECHANISM
|
Dolasetron_ddi.xml
|
DDI-DrugBank.d42.s1
|
DDI-DrugBank.d42.s1.p4
|
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
|
salicylates
|
sulfonamide antibiotics
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s1
|
DDI-DrugBank.d313.s1.p51
|
Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
|
Praziquantel
|
praziquantel
|
NONE
|
Albendazole_ddi.xml
|
DDI-DrugBank.d321.s1
|
DDI-DrugBank.d321.s1.p0
|
The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.
|
nevirapine
|
antithrombotic agent
|
NONE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s9
|
DDI-DrugBank.d270.s9.p0
|
Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
|
nicotine
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s6
|
DDI-DrugBank.d488.s6.p13
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
NSAIDs
|
antidiabetic drugs
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p10
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
glucagon
|
phenylbutazone
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p939
|
Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
|
Benzodiazepines
|
fluvoxamine
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s12
|
DDI-DrugBank.d76.s12.p8
|
Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.
|
Alcohol
|
SINEQUAN
|
NONE
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s26
|
DDI-DrugBank.d223.s26.p1
|
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
|
troleandomycin
|
corticosteroids
|
MECHANISM
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s2
|
DDI-DrugBank.d487.s2.p1
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
aminoglycosides
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p4
|
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.
|
phenytoin
|
quinidine
|
NONE
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s3
|
DDI-DrugBank.d29.s3.p6
|
Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.
|
atorvastatin
|
aliskiren
|
MECHANISM
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s3
|
DDI-DrugBank.d533.s3.p0
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
|
phenothiazines
|
contraceptives
|
NONE
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s1
|
DDI-DrugBank.d536.s1.p32
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
lincomycin
|
quinidine
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p76
|
Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
|
eplerenone
|
verapamil
|
MECHANISM
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s3
|
DDI-DrugBank.d20.s3.p1
|
Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.
|
azole antifungal agents
|
isoniazid
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s24
|
DDI-DrugBank.d165.s24.p0
|
Coadministration of fluoxetine significantly decreased cisapride plasma concentrations.
|
fluoxetine
|
cisapride
|
MECHANISM
|
11213850.xml
|
DDI-MedLine.d46.s13
|
DDI-MedLine.d46.s13.p0
|
Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
|
Digoxin
|
Adenocard
|
EFFECT
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s1
|
DDI-DrugBank.d226.s1.p1
|
However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
|
PRECEDEX
|
sedative
|
ADVISE
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s4
|
DDI-DrugBank.d197.s4.p6
|
Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.
|
pseudoephedrine
|
digitalis
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s5
|
DDI-DrugBank.d448.s5.p0
|
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
|
Nalfon
|
Nalfon
|
NONE
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s2
|
DDI-DrugBank.d154.s2.p12
|
Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
|
Clonidine
|
clonidine
|
NONE
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s4
|
DDI-DrugBank.d269.s4.p0
|
Theophylline: Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days.
|
Theophylline
|
ceftibuten
|
NONE
|
Ceftibuten_ddi.xml
|
DDI-DrugBank.d32.s0
|
DDI-DrugBank.d32.s0.p0
|
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.
|
Tricyclic antidepressants
|
clonidine
|
EFFECT
|
Brimonidine_ddi.xml
|
DDI-DrugBank.d138.s3
|
DDI-DrugBank.d138.s3.p0
|
Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
|
quinolones
|
theophylline
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s16
|
DDI-DrugBank.d123.s16.p5
|
Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.
|
cimetidine
|
nifedipine
|
MECHANISM
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s11
|
DDI-DrugBank.d373.s11.p5
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
benzodiazepines
|
phenothiazines
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p9
|
Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
|
SSRIs
|
doxepin
|
MECHANISM
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s16
|
DDI-DrugBank.d223.s16.p5
|
Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
|
Azlocillin
|
ciprofloxacin
|
ADVISE
|
Azlocillin_ddi.xml
|
DDI-DrugBank.d9.s0
|
DDI-DrugBank.d9.s0.p1
|
Probenecid depresses tubular secretion of certain weak acids such as PAH.
|
Probenecid
|
PAH
|
MECHANISM
|
Aminohippurate_ddi.xml
|
DDI-DrugBank.d416.s2
|
DDI-DrugBank.d416.s2.p0
|
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
|
Furosemide
|
succinylcholine
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s4
|
DDI-DrugBank.d231.s4.p1
|
Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
|
PRINIVIL
|
triamterene
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s15
|
DDI-DrugBank.d334.s15.p2
|
However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis.
|
Xigris
|
Xigris
|
NONE
|
Drotrecogin alfa_ddi.xml
|
DDI-DrugBank.d190.s1
|
DDI-DrugBank.d190.s1.p0
|
Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
|
fenofibrate
|
atorvastatin
|
MECHANISM
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s15
|
DDI-DrugBank.d283.s15.p1
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
isoniazid
|
clarithromycin
|
NONE
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p74
|
Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
|
sympathomimetics
|
MAO inhibitors
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s3
|
DDI-DrugBank.d389.s3.p0
|
Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;
|
FOSCAVIR
|
pentamidine
|
EFFECT
|
Foscarnet_ddi.xml
|
DDI-DrugBank.d511.s1
|
DDI-DrugBank.d511.s1.p0
|
Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.
|
rifampin
|
diltiazem
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s41
|
DDI-DrugBank.d565.s41.p0
|
Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
|
probenecid
|
acyclovir
|
MECHANISM
|
Aciclovir_ddi.xml
|
DDI-DrugBank.d200.s0
|
DDI-DrugBank.d200.s0.p0
|
Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
|
Albuterol
|
albuterol
|
NONE
|
Atomoxetine_ddi.xml
|
DDI-DrugBank.d11.s0
|
DDI-DrugBank.d11.s0.p3
|
Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
|
ALPHAGAN P
|
alcohol
|
ADVISE
|
Brimonidine_ddi.xml
|
DDI-DrugBank.d138.s0
|
DDI-DrugBank.d138.s0.p1
|
Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
|
cimetidine
|
rofecoxib
|
MECHANISM
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s10
|
DDI-DrugBank.d210.s10.p2
|
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
|
ergot-type medications
|
naratriptan
|
ADVISE
|
Naratriptan_ddi.xml
|
DDI-DrugBank.d478.s1
|
DDI-DrugBank.d478.s1.p6
|
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
|
Didanosine
|
carbamazepine
|
NONE
|
Delavirdine_ddi.xml
|
DDI-DrugBank.d251.s0
|
DDI-DrugBank.d251.s0.p13
|
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
|
retinyl acetate
|
insulin
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s0
|
DDI-MedLine.d12.s0.p4
|
Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
|
capecitabine
|
coumarin-derivative anticoagulants
|
EFFECT
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s3
|
DDI-DrugBank.d88.s3.p4
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
lincomycin
|
anesthetics
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p74
|
The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
|
enoximone
|
anagrelide
|
EFFECT
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s14
|
DDI-DrugBank.d75.s14.p8
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
sulfonamides
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p12
|
Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
|
beta-adrenergic blocking agents
|
calcium antagonists
|
ADVISE
|
Levobunolol_ddi.xml
|
DDI-DrugBank.d252.s2
|
DDI-DrugBank.d252.s2.p0
|
Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.
|
rifampin
|
zaleplon
|
MECHANISM
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s16
|
DDI-DrugBank.d324.s16.p0
|
Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.
|
quinolones
|
cyclosporine
|
MECHANISM
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s13
|
DDI-DrugBank.d427.s13.p2
|
These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.
|
lead
|
alcohol
|
EFFECT
|
6536282.xml
|
DDI-MedLine.d93.s9
|
DDI-MedLine.d93.s9.p0
|
Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
|
spironolactone
|
potassium
|
NONE
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s15
|
DDI-DrugBank.d334.s15.p11
|
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
|
antimuscarinics
|
antihistamines
|
NONE
|
Hyoscyamine_ddi.xml
|
DDI-DrugBank.d142.s0
|
DDI-DrugBank.d142.s0.p12
|
Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
|
Ephedrine
|
Ephedrine
|
NONE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s16
|
DDI-DrugBank.d314.s16.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.